Medical Marijuana Market

Aurora Cannabis lifted global medical cannabis net revenue 18% to CAD 288.6 million in fiscal 2026, with CAD 176.5 million earned outside Canada, according to its results filed with the SEC on Form 6-K. Exporters now chase patients rather than shoppers. The medical marijuana market covers cannabis flower, extracts, oral and topical formulations and approved cannabinoid drugs dispensed to patients under a clinician authorisation, a state or national patient program, or a pharmacy prescription; adult-use sales and hemp wellness CBD are excluded. Our 2025 figure is USD 13.50 billion, built as 5.84 million patient-years of treatment at an average realised USD 2,312 each. Revenue compounds at 6.74% a year to USD 25.9 billion in 2035. The federal turn came on 22 April 2026, when the Drug Enforcement Administration (DEA) signed an order, effective 28 April 2026, placing FDA-approved marijuana products and state-licensed medical marijuana in Schedule III (91 FR 22715). The study belongs to our pain management therapeutics coverage, and every number follows the Douglas Insights research methodology.

What sits inside the medical marijuana perimeter, and what stays out?

Medical marijuana here means 5.84 million patient-years of authorised treatment in 2025, spanning dispensary flower, pharmacy extracts and approved cannabinoid drugs. Adult-use sales, hemp-derived CBD wellness goods and synthetic THC variants stay outside, because none of them needs a clinician’s authorisation, a patient card or a medical licence to reach a buyer.

A patient-year is one patient supplied for twelve months. Germany shows why the unit matters: its importers brought in 201,094 kg of medical cannabis last year on Federal Institute for Drugs and Medical Devices (BfArM) data, enough for about 0.55 million patients at 1 gram a day. Registry headcounts overstate use, because many card holders buy only a few times a year.

The product axis has four lines: Dried flower; Oils, extracts and vape cartridges; Capsules, edibles and topicals; and Approved cannabinoid drugs. The indication axis runs from Chronic pain through Anxiety and sleep, Epilepsy, Multiple sclerosis spasticity and Chemotherapy nausea to Other indications. Three routes carry product: Dispensaries, Pharmacies and Licensed producer direct mail.

Who sells the most medical marijuana: dispensary chains, licensed producers or Jazz?

Jazz Pharmaceuticals, Trulieve, Curaleaf, Aurora Cannabis, Canopy Growth and Tilray lead medical marijuana supply, and Douglas Insights estimates the top three hold 21.4% of 2025 revenue. Concentration stays low because US state licences cap retail footprints and German pharmacies buy from many importers and only three domestic growers.

Jazz is the single largest seller. Epidiolex, its cannabidiol oral solution, reached net product sales of USD 1.1 billion in 2025, up 9%, as Jazz reported on 24 February 2026; that equals an 8.1% share of the medical marijuana total. Canopy Growth booked CAD 90.8 million of Canada medical cannabis revenue in fiscal 2026, up 18%, after buying MTL Cannabis. Aurora, with CAD 288.6 million of medical revenue, earns CAD 176.5 million of it outside Canada.

Trulieve runs 162 of its 233 dispensaries in Florida, the largest patient registry in the US, and reported USD 1.2 billion of revenue for its latest year; Douglas Insights attributes USD 918.1 million of that, a 6.8% market share, to medical card holders. Curaleaf operates 159 US stores, 69 of them in Florida, plus European medical markets, for an estimated 6.5% share. Tilray Medical supplies 20 countries and grows in Neumünster, one of Germany’s three licensed cultivation sites, where it has launched its German-grown ARX brand.

The Schedule III order also reshapes competition. It set up an expedited federal registration route for state medical licensees, which favours multi-state operators with compliance teams over single-store owners.

Which medical marijuana product format makes the money: dried flower, extracts or Epidiolex?

Dried flower makes the most money, with 41.7% of 2025 medical marijuana revenue, or USD 5.63 billion. Oils, extracts and vape cartridges grow fastest at 8.64% a year, because German and Australian prescribers favour metered doses and Israel’s health committee wants smoked product phased out.

Dried flower holds USD 5.63 billion because Florida, Oklahoma and German pharmacy patients still buy smokable or vaporisable buds by the gram. Its 4.77% growth is the slowest, as per-gram flower prices fall each year.

Oils, extracts and vape cartridges carry USD 4.67 billion, and their 8.64% rate lifts them past flower around 2031 in our model. Metered dosing is the reason: a measured capsule or vape is easier for a prescriber to chart than smoked flower. Capsules, edibles and topicals add USD 1.78 billion, rising 7.18% a year as older patients avoid inhalation.

Approved cannabinoid drugs total USD 1.42 billion, and Epidiolex is roughly 78% of that line. They grow 6.87% a year: paediatric seizure demand compounds steadily, while generic dronabinol and nabilone prices keep the rest flat.

How do chronic pain, epilepsy and spasticity split the medical marijuana patient base?

Chronic pain accounts for 56.3% of medical marijuana patient-years in 2025, Douglas Insights estimates, about 3.29 million of the 5.84 million total. Anxiety and sleep follow at 17.8%, while Epilepsy takes 9.4% of patient-years but a larger slice of revenue, because prescription cannabidiol costs far more per patient than flower.

Chronic pain dominance links medical marijuana to opioid-sparing strategies tracked in our Pain Management Devices Market and Acetaminophen Market reports. Epilepsy demand is narrower and better evidenced, and the paediatric seizure patients counted in the Grand Mal Seizure Market study overlap with Epidiolex users.

How do medical marijuana patients reach a dispensary, a pharmacy or a mail-order licensed producer?

Dispensaries carry 68.4% of medical marijuana revenue in 2025, because 3.69 million US registry patients buy at state-licensed stores. Pharmacies take 24.9%, led by Germany and Australia, and Licensed producer direct mail holds 6.7%, almost all of it Canada’s federal medical system.

Canada runs the purest mail-order model. Health Canada’s latest count shows 161,267 active client registrations with federally licensed sellers and 11,304 people registered to grow their own, with seller clients authorised an average 2.5 grams a day. Florida, by contrast, lists 939,639 qualified patients with active ID cards served through 776 dispensing locations.

Why are medical marijuana registries still growing after the Schedule III order?

Volume grows 7.6% a year to 2035, from 5.84 million to 12.1 million patient-years, as pharmacy-led markets in Europe and new national programs add patients faster than US registries lose them to adult-use stores. Four drivers supply that 7.6-point volume leg.

US federal reclassification of licensed medical cannabis: 2.6 points

The Schedule III order adds 2.6 points to medical marijuana volume growth in our model. For the first time, state-licensed medical product sits in a lower federal schedule than adult-use product, which gives operators a reason to keep the medical card alive. Trulieve’s 162 Florida stores and Curaleaf’s 69 sit in a state with 939,639 active card holders and no adult-use sales, so Florida alone anchors about one quarter of US medical patients. Research access widens too, because Executive Order 14370, signed on 18 December 2025, asked agencies to speed cannabidiol and marijuana studies, which feeds the clinical evidence physicians want before they authorise.

German and wider European pharmacy demand: 2.3 points

European pharmacy demand contributes 2.3 points. German imports rose 2.76-fold between the two latest full years, from 72,850 kg to 201,094 kg, after the 2024 Medical Cannabis Act (MedCanG) eased patient access. Each 10,000 kg of extra imports equals roughly 27,400 patient-years at 1 gram a day, so the import curve is the best single gauge of German demand. Canada supplied 93,006 kg of that, about 46%, and Portugal 55,164 kg. Aurora’s CAD 176.5 million of international medical revenue shows how much of the pull is export-led.

New national programs in Asia Pacific and Latin America: 1.5 points

New and maturing national programs add 1.5 points. Australia’s medicinal cannabis market crossed AUD 1.1 billion last year, with Therapeutic Goods Administration (TGA) Special Access Scheme Category B (SAS-B) approvals running above 23,000 a month in the first half and more than 1,700 authorised prescribers. Latin American programs start from a USD 268.9 million base and add patients at double-digit rates in our model.

Approved cannabinoid drug uptake: 1.2 points

Prescription cannabinoids supply the last 1.2 points. Epidiolex grew 9% last year to USD 1.1 billion, and each added paediatric patient on a branded cannabidiol script is worth several flower patients in revenue. Douglas Insights expects approved cannabinoid drugs to reach USD 2.76 billion by 2035, nearly double the USD 1.42 billion of 2025.

What limits medical marijuana volume as telehealth prescribing and veteran reimbursement tighten?

Three restraints remove a combined 4.2 points from gross medical marijuana volume growth of 11.8%, leaving the 7.6% base. The largest is US adult-use legalisation, which pulls card holders into recreational stores, followed by German curbs on remote prescribing and tighter payer rules in Canada and Israel.

Adult-use cannibalisation removes 1.9 points. Every US state that opens recreational sales sees medical registrations fall, because the card stops saving money once tax gaps narrow; Oklahoma, Pennsylvania and Florida, with 310,850, 441,530 and 939,639 patients respectively, are the large programs still without adult-use stores. German telemedicine limits remove 1.4 points. On 8 October 2025 the federal cabinet adopted a bill requiring in-person contact before a first medical cannabis prescription and banning mail delivery of flower, after imports rose more than 400% in a half-year, from about 19 to 80 tonnes, while statutory insurance prescriptions rose only in single digits. The Bundesrat held its first pass on 21 November 2025 and the Bundestag its first reading on 18 December 2025.

Payer pressure removes 0.9 points. As the Veterans Affairs Canada policy page shows, the department reimbursed 27,643 veterans in its latest fiscal year and cut its per-gram ceiling by 29.4%, and Israel’s committee proposal to phase out smoked product for 140,000 licensees, 87% of whom smoke, was halted by the health minister on 6 May 2026.

Where do medical marijuana dispensary and pharmacy dollars concentrate by region?

North America holds 71.2% of medical marijuana revenue, USD 9.62 billion in 2025, on the back of 3.69 million registered US patients and Canada’s federal program. Latin America is the fastest-growing region at 10.37% a year, from a small base, and Europe adds the most new dollars.

North America grows only 5.56% a year to USD 16.5 billion, because adult-use stores absorb part of each mature registry. Douglas Insights puts Canada at USD 412.6 million of the regional total, with the US at USD 9.21 billion.

Europe more than doubles from USD 2.31 billion to USD 5.96 billion at 9.93% a year; Germany alone is about USD 1.68 billion in our estimate. Asia Pacific reaches USD 2.26 billion at 8.68%, with Australia the core.

Latin America climbs from USD 268.9 million to USD 721.3 million, as national programs widen patient access from a low base. The wildcard is the Middle East and Africa, at USD 320.9 million: Israel’s 140,000 licensees make it a real market, but a forced shift away from smoked flower would cut growth to 3.66% or below.

How much does a gram of medical marijuana cost a patient, a veteran or an insurer?

Medical marijuana realises an average USD 2,312 per patient-year in 2025, falling 0.8% a year to USD 2,134 by 2035. Payer ceilings set the floor in Canada, where Veterans Affairs Canada cut its reimbursement maximum from CAD 8.50 to CAD 6.00 per gram for products ordered from 1 April 2026.

At Health Canada’s average authorisation of 2.5 grams a day, the old ceiling paid up to CAD 7,756 a year per veteran and the new one CAD 5,475. Douglas Insights estimates realised US dispensary flower at USD 5.80 to USD 9.40 per gram for card holders, German pharmacy flower at EUR 7.90 to EUR 13.60 per gram before insurer discounts, and branded cannabidiol at well over USD 20,000 per treated patient-year.

The 0.8% annual price decline blends falling flower prices with a rising mix of extracts and branded drugs. Flower drops about 3% a year in our model; extracts hold roughly flat.

Which medical marijuana rules changed when the DEA moved licensed medical cannabis to Schedule III?

Two US categories now sit in Schedule III: FDA-approved marijuana drug products and marijuana held under a state medical-only licence. Adult-use marijuana, hemp products and synthetic THC stayed in place, so a medical marijuana licence now carries federal weight that a recreational licence lacks.

The path ran through the White House. Executive Order 14370, signed on 18 December 2025, directed the Attorney General to complete rescheduling to Schedule III. The DEA then held an 11-day evidentiary hearing from 29 June to 15 July 2026 on moving all remaining marijuana, and a broader decision remains open in the law-firm analysis we read, after the Federal Register order.

Germany regulates medical cannabis through MedCanG, which treats it as a prescription medicine sold by pharmacies under EU good manufacturing practice (EU-GMP). Canada licenses sellers federally and lets patients register with them directly.

What if Schedule III widens to all marijuana: the 2035 medical cannabis forecast in three cases?

Three cases bracket 2035 medical marijuana revenue between USD 18.9 billion and USD 34.6 billion, with the base at USD 25.9 billion. The base keeps volume at 7.6% and price at minus 0.8%; the swing depends on how US registries react if the DEA reschedules adult-use marijuana as well.

In the slower case, full rescheduling erases the federal advantage of the medical card created by the Schedule III order, Germany passes its telemedicine curbs and flower prices fall 1.6% a year, leaving USD 18.9 billion. In the faster case, Spain, France and Turkey open medical programs, insurers in Europe widen coverage and volume reaches 10.2% a year, producing USD 34.6 billion.

Volume sensitivity is steep: one extra point of annual patient growth lifts 2035 revenue by USD 2.51 billion, and one point less removes USD 2.31 billion. Our 6.74% is less than half the 15.4% low end of published forecasts, which reach 30.5%; the gap comes from excluding adult-use sales and pricing flower at falling realised levels.

Douglas Exclusive: the Medical Marijuana Rulemaking Calendar 2024-2027

The Medical Marijuana Rulemaking Calendar is a Douglas Insights model, not an official register. It is built from 19 inputs, namely 12 dated events and 7 exposure estimates, each event taken from the sources cited on this page, and it attaches a Douglas Insights estimate of the 2025 revenue each event touches, so a buyer can see which decision moves the most money.

The finding: two items still open in the sources we read, the German amendment, which the ministry lists as an ongoing procedure after its first reading, and the DEA decision on all marijuana, together touch USD 10.9 billion, or 80.7% of 2025 medical marijuana revenue. Douglas Insights therefore treats 2027 as the year the forecast is most likely to be re-based.

How we built the medical marijuana model from 5.84 million patient-years?

The medical marijuana model multiplies 5.84 million patient-years by USD 2,312 to reach USD 13.50 billion in 2025, then grows volume 7.6% and price minus 0.8% a year. Patient-years come from registry and import data for five countries plus US state programs; price comes from company revenue and payer ceilings.

Volume inputs were 3,693,596 US registry patients, 939,639 Florida card holders, 172,571 Canadian registrations, 201,094 kg of German imports converted at 1 gram a day, 140,000 Israeli licences and Australian SAS-B approval rates. Price inputs were Epidiolex sales of USD 1.1 billion, Aurora and Canopy medical revenue, Trulieve revenue and the Veterans Affairs Canada CAD 8.50 and CAD 6.00 ceilings.

Three cross-checks were run. Epidiolex alone equals 77.6% of the USD 1.42 billion approved-drug line, consistent with Jazz’s disclosed sales. At an assumed 0.65 US dollars per Australian dollar, the AUD 1.1 billion Australian figure is 72.9% of the USD 981.3 million Asia Pacific value. Canada’s 172,571 registrations at 2.5 grams a day and the CAD 6.00 ceiling give an upper bound of CAD 945 million, above our USD 412.6 million estimate, as expected when patients buy less than their authorisation. The 2025 to 2026 step is USD 13.50 billion to USD 14.4 billion.

Sources

1. Drug Enforcement Administration Schedules of Controlled Substances: Rescheduling of FDA Approved Products Containing Marijuana, 91 FR 22715 (2026)
2. The White House Executive Order 14370, Increasing Medical Marijuana and Cannabidiol Research (2025)
3. SEC EDGAR Aurora Cannabis fiscal 2026 results, Form 6-K exhibit 99.1 (2026)
4. SEC EDGAR Canopy Growth fiscal 2026 results, Form 8-K exhibit 99.1 (2026)
5. Jazz Pharmaceuticals Jazz Pharmaceuticals full year 2025 results (2026)
6. SEC EDGAR Trulieve Form 10-K for 2025 (2026)
7. Bundesministerium fuer Gesundheit Kabinett beschliesst Aenderung des Medizinal-Cannabisgesetzes (2025)
8. Health Canada Data on cannabis for medical purposes (2025)
9. Veterans Affairs Canada Cannabis for medical purposes, revised reimbursement policy (2026)
10. Florida Department of Health OMMU weekly update, 21 August 2026 (2026)
11. Tilray Brands Tilray Medical Germany launches ARX (2026)